Scarica l'app Stockscreener
28.22
1.04%
0.29
Dopo l'orario di chiusura:
28.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$27.93
Aprire:
$27.89
Volume 24 ore:
2.30M
Relative Volume:
0.98
Capitalizzazione di mercato:
$3.56B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-13.90
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+6.17%
1M Prestazione:
+44.05%
6M Prestazione:
+8.54%
1 anno Prestazione:
-28.74%
Intervallo 1D:
$27.74
$28.52
Intervallo di 1 settimana:
$26.23
$28.52
Portata 52W:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
28.22 | 3.53B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Real time social sentiment graph for Apellis Pharmaceuticals Inc.Portfolio Return Summary & Low Risk Investment Opportunities - Newser
Apellis Pharmaceuticals Inc. stock momentum explainedEarnings Overview Summary & AI Powered Market Trend Analysis - Newser
Will Apellis Pharmaceuticals Inc. stock recover after recent dropPortfolio Performance Report & Low Drawdown Investment Strategies - Newser
Can machine learning forecast Apellis Pharmaceuticals Inc. recovery2025 Biggest Moves & Free Safe Capital Growth Stock Tips - Newser
Stocks To Watch: Apellis Pharmaceuticals Sees Relative Strength Rating Rise To 81 - MSN
Has Apellis Pharmaceuticals Inc. formed a bullish divergenceWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
Published on: 2025-08-27 10:23:38 - Newser
Chart based exit strategy for Apellis Pharmaceuticals Inc.Dollar Strength & Stepwise Entry and Exit Trade Signals - Newser
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences | APLS Stock News - GuruFocus
When is the best time to exit Apellis Pharmaceuticals Inc.Trade Signal Summary & Consistent Return Strategy Ideas - Newser
Can Apellis Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Volume Summary & Daily Stock Momentum Reports - beatles.ru
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Leader Apellis Pharmaceuticals Announces Triple Conference Schedule for September 2025 - Stock Titan
Key metrics from Apellis Pharmaceuticals Inc.’s quarterly dataJuly 2025 Weekly Recap & Fast Momentum Entry Tips - Newser
Using data filters to optimize entry into Apellis Pharmaceuticals Inc.Weekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
Can Apellis Pharmaceuticals Inc. recover in the next quarter2025 Market Overview & Long-Term Growth Stock Strategies - Newser
How to use Fibonacci retracement on Apellis Pharmaceuticals Inc.Exit Point & Fast Exit and Entry Trade Guides - Newser
Sentiment Tools Show Shift in Trader Mood on Apellis Pharmaceuticals Inc. getLinesFromResByArray error: size == 0 - metrotimes.co.kr
Chart overlay techniques for tracking Apellis Pharmaceuticals Inc.CEO Change & AI Based Buy and Sell Signals - Newser
What data driven models say about Apellis Pharmaceuticals Inc.’s futureJuly 2025 Action & Stepwise Trade Signal Implementation - Newser
Is Apellis Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 Rallies & AI Driven Stock Reports - Newser
Signal strength of Apellis Pharmaceuticals Inc. stock in tech scannersJuly 2025 Technicals & Fast Exit and Entry Trade Guides - Newser
Heatmap analysis for Apellis Pharmaceuticals Inc. and competitorsMarket Performance Summary & Capital Protection Trading Alerts - Newser
How to track smart money flows in Apellis Pharmaceuticals Inc.Weekly Trend Report & Verified Technical Trade Signals - Newser
Institutional scanner results for Apellis Pharmaceuticals Inc.July 2025 Sector Moves & Low Risk High Win Rate Stock Picks - Newser
What earnings revisions data tells us about Apellis Pharmaceuticals Inc.July 2025 Sector Moves & Reliable Breakout Forecasts - Newser
Can momentum traders help lift Apellis Pharmaceuticals Inc.2025 Technical Patterns & Reliable Price Action Trade Plans - Newser
Backtesting results for Apellis Pharmaceuticals Inc. trading strategiesJuly 2025 Outlook & Weekly Top Gainers Alerts - Newser
Earnings call transcript: Apellis Pharmaceuticals Q2 2025 beats EPS forecast, stock surges - Investing.com
Will Apellis Pharmaceuticals Inc. stock benefit from interest rate changes2025 Price Momentum & Weekly High Return Stock Forecasts - Newser
Will Apellis Pharmaceuticals Inc. Benefit From Broader Market Bounce2025 Earnings Surprises & Advanced Technical Analysis Signals - beatles.ru
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Is it too late to sell Apellis Pharmaceuticals Inc.Weekly Profit Analysis & Expert Curated Trade Setup Alerts - Newser
Apellis Pharmaceuticals General Counsel Watson David O. sells 5000 shares at $27.8 on 2023-08-18. - AInvest
What momentum shifts mean for Apellis Pharmaceuticals Inc.July 2025 Earnings & Expert Verified Movement Alerts - Newser
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):